KR101972462B1 - Composition having Enzyme Treated Extract of Clove - Google Patents

Abstract

The present invention is characterized in that the clove extract of the above-mentioned enzyme treatment comprises water, a lower alcohol of C1 to C2 or a lower alcohol of C1 to C2, And further characterized in that the lower alcohol is ethanol or methanol. The composition extracted in the above process may be selected from sugar alcohols, lipid loosens, Is selectively added to eliminate enzyme activity.
According to the present invention, the DPPH inhibitory activity, the promotion of the generation of Type-1 procollagen in human dermal fibroblast (HDF), the prevention of skin aging and wrinkles by the effect of inhibiting the production of MMP-1 and MMP- It exhibits an improving effect and does not exhibit a change in cell survival rate, thereby securing an excellent safety.

Description

[0001] The present invention relates to a composition containing an enzyme-treated clove extract,

More particularly, the present invention relates to a composition containing an enzyme-treated clove extract as an active ingredient, which contains an enzyme-treated clove extract to improve skin wrinkles and prevent skin aging.

The human skin consists largely of the epidermis, the dermis, and the subcutaneous fat layer. The most basic role of the skin is to prevent water from evaporating from our body and to prevent harmful substances from invading from the outside. These skin are always exposed to external stimuli, so they have various defenses.

In addition, skin is a representation of beauty, and skin is healthy and clean is often recognized as human beauty. In recent years, not only women but also men have been interested in various skin troubles such as skin aging, and a lot of related products are being developed.

Skin aging can be roughly classified into two types. The first is intrinsic aging, a phenomenon of aging that can not be avoided as years go by. The second is photoaging, which refers to the aging phenomenon observed in the skin such as the face, the back of the hand, and the back of the neck exposed to sunlight for a long time, resulting from the combination of the effects of endogenous aging and ultraviolet rays.

It is known that the cause of skin aging is a collapse of matrix proteins such as collagen and elastic fibers, resulting in deficiency of collagen in the skin and denaturation of elastic fibers. It is also known that during the process of skin aging, the synthesis of collagen is reduced through various signal transduction pathways and the expression of matrix metalloproteinases (MMPs), a degradation enzyme of extracellular matrix proteins including collagen, is increased. As such, collagen is recognized as a major factor related to skin aging, and inhibition of synthesis and inhibition of collagen synthesis is an important indicator for skin aging suppression and skin beauty.

These MMPs are calcium and zinc-dependent endopeptidases secreted from cells such as POIMOLMONTONUCLEOUS neutrophil, macrophage, and fibroblast, which act at neutral pH, The substrate of the egg cell is used. MMP-1, MMP-3, and MMP-9 are the most active enzymes in the skin, and MMP-1 is the most fundamental enzyme involved in collagen degradation.

In general, there are retinoids (RE36068), TGF-beta (transforming growth factor), betulinic acid (JP8-208424), and the like, which inhibit the production of MMP- β (transforming growth factor), and various other natural products are known to inhibit MMP-1 biosynthesis. Therefore, a method for inhibiting wrinkle formation can be used, which promotes collagen synthesis, or inhibits the production and activity of collagenase, and it is urgently required to develop a cosmetic for more effective, easy and safe wrinkle reduction.

Recent studies have shown that the expression of ultraviolet-stimulated cytokines (such as IL-6) affects the aging indexes such as MMP-1 and MMP-3. (Hwang E, Kim SH, Lee S, Lee CH, Do SG, Kim J, Kim S. A Comparative Study of Baby Immature and Adult Shoots of Aloe Vera on UVB-Induced Skin Photoaging in vitro. It has been reported that the expression of Type-1 Procollagen is also inhibited by ultraviolet irradiation.

In Korea, antioxidant, anti-obesity and antidiabetic effects have been reported based on herbal studies of Syzygiumaromaticum. Cloves are cloves and grapes belonging to the country of origin is Indonesia, but now India, Malaysia, Sri Lanka, Brazil and is being cultivated in the coastal areas of the country. Efforts are being made to utilize extracts in cosmetics, medicines and foods, as well as in the study of cloves.

Korean Patent Registration No. 2015-0115515 (Prior Art 1) and Korean Patent Registration No. 1456052 (Prior Art 2) are known as prior art documents which can be referred to in this connection.

The prior art document 1 discloses a process for producing a clove extract comprising: (a) extracting cloves with a solvent to obtain an clove solvent extract; (b) removing the solvent from the clove solvent extract; And (c) treating the extract from which the solvent has been removed with a hydrolytic enzyme to obtain an enzyme-treated clove extract.

This study was conducted to investigate the effect of ginseng on the growth of ginseng, ginseng, peony, ginseng, ginseng, pineapple, ginseng, The present invention provides a cosmetic composition for improving wrinkles comprising as an active ingredient, a fermented extract of a medicinal substance selected from the group consisting of cloves, sculptors, dermis, creams, tansan liquor, silkworm, persimmons, runners and red ginseng.

However, in the case of the prior art document 1, the effect of improving the wrinkle is unknown because the antioxidant ability is expressed, and in the case of the preceding document 2, the limit is limited to cosmetic products based on general purpose medicines not specific to clove.

1. Korean Patent Registration No. 2015-0115515 entitled " Antioxidant composition containing an enzyme-treated extract of cloves " (published on Oct. 14, 2015). 2. Korean Patent Registration No. 1456052 entitled " Composition for improving wrinkles " (published on October 23, 2008).

It is an object of the present invention to overcome the above-mentioned problems of the prior art by providing an extract of clove which is capable of exhibiting a stable effect in foods and medicines as well as cosmetics while exhibiting excellent functions in terms of skin wrinkles and anti- And a method for producing the same.

In order to achieve the above object, the present invention is produced so as to contain a clove extract of an enzyme treatment as an active ingredient through extraction, filtration and concentration of the raw material of the clove.

As a detailed constitution of the present invention, the above-mentioned clove extract of the enzyme treatment is characterized by being extracted with water, various kinds of lower alcohols or a mixed solvent thereof.

In another specific embodiment of the present invention, the lower alcohol is ethanol or methanol.

As a detailed constitution of the present invention, the composition extracted in the above process is characterized in that the enzyme activity is lost by selectively adding a sugar disintegration, a lipid disintegration, and a pack disintegration.

In another embodiment of the present invention, the enzyme is selected from the group consisting of Alpha-Galactosidase, Peclivel LI (pecinase, Cellulase), Filterase Premium L, Tannase KTFH, Cellulase ), KN, Crystalzyme PMLX, Celluyve AN 3500 (cellulase), Rapidase FP super (pectin methyl esterase), Bio Win G (PL) and Sumizyme AC .

As a detailed constitution of the present invention, the above-mentioned composition is added in an amount of 1 to 15% by weight based on the total weight of the finished product in the case of cosmetics and 0.001 to 50% by weight based on the total weight of the finished product in the case of pharmaceuticals .

According to the present invention, the DPPH inhibitory activity, the promotion of the generation of Type-1 procollagen in human dermal fibroblast (HDF), the prevention of skin aging and wrinkles through the effect of inhibiting the production of MMP-1 and MMP- It exhibits an improving effect and does not exhibit a change in cell survival rate, thereby securing an excellent safety.

Furthermore, the enzyme-treated clove extract obtained according to the production method of the present invention has an action and effect that can be advantageously utilized as a composition to be added to cosmetics as well as foods, medicines and the like.

FIG. 1 is a graph showing the results of HLPC analysis of an untreated clove extract and an enzyme treated clove extract of an enzyme,
FIG. 2 is a graph showing DPPH radical inhibitory activity of the enzyme-treated clove extract according to Test Example 1,
FIG. 3 is a graph showing the results of an experiment of cell survival rate after irradiation with ultraviolet rays of an enzyme-treated clove extract performed according to Test Example 2,
FIG. 4 is a graph showing the results of confirming the expression level of MMP-1 in the enzyme-treated clove extract according to Test Example 3. FIG.
FIG. 5 is a graph showing the results of confirming the expression level of MMP-3 in the enzyme-treated clove extract according to Test Example 4. FIG.
FIG. 6 is a graph showing the results of confirming the expression level of IL-6 in the enzyme-treated clove extract according to Test Example 4. FIG.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.

The present invention provides a cosmetic, a food, and a pharmaceutical composition for improving skin wrinkles containing an enzyme-treated clove extract as an active ingredient. The applicant of the present invention studied the composition of cosmetic products, foods and medicines for improving skin wrinkles in the past, and found out that the enzyme-treated clove extract exhibits excellent anti-aging activity of the skin, and thus completed the present invention .

More specifically, it contains DPPH inhibitory activity, promotion of type-1 procollagen production, reduction of MMP-1 and MMP-3 production by containing enzyme-treated clove extract as an active ingredient, And a composition of food, medicine, and cosmetic for improving wrinkles.

In the composition of the present invention, the above-mentioned extract can be obtained by an extraction method comprising extracting an enzyme-treated clove as an extraction solvent with water, a C1-C4 alcohol, or a mixed solvent of C1-C4 alcohol and water. In one embodiment, the extraction solvent is an aqueous solution of ethanol.

The enzymes include, but are not limited to, Alpha-Galactosidase, Peclone LI, Filterase Premium L, Tannase KTFH, Cellulase KN, Crystalzyme PMLX, Celluyve AN 3500 (cellulase), Rapidase FP super (pectin methyl esterase) , Sumizyme AC, but is not limited thereto. The extract is preferably added in an amount of 5 g (ml) to 20 g (ml) / 100 ml, more preferably 10 g (ml) / 100 ml, but not always limited thereto. The enzyme is preferably reacted at a pH of 5.0 to 6.5 at 40 to 50 ° C, more preferably at a pH of 5.2 to 6.0 and at a temperature of 42 to 45 ° C, but is not limited thereto. The reaction time is preferably 1 to 3 hours, more preferably 1.5 hours, but is not limited thereto.

It is preferable that the enzyme-treated clove extract is extracted with a solvent in which each of the organic solvents is mixed with water as a solvent, and then the enzyme activity is lost by adding sugar alcohols, releasing lipids and releasing packed fractions.

The enzyme-treated clove extract is preferably, but not necessarily, prepared by a manufacturing method comprising the following steps.

1) extracting an enzyme-treated clove by adding an extraction solvent;

2) cooling the extract of step 1) and filtering;

3) concentrating the filtered extract of step 2) under reduced pressure; And

4) dry-pulverizing the concentrated extract of step 3).

In the above method, the enzyme-treated clove of step 1) can be used without limitation such as cultivated or commercially available. The enzyme-treated clove is preferably, but not always, a leaf, seed, fruit, root or aerial part.

In the composition according to the present invention, the extract may be obtained by an extraction method comprising extracting an enzyme-treated clove as an extraction solvent with water, a C1-C4 alcohol, or a mixed solvent of C1-C4 alcohol and water. In one embodiment, the extraction solvent may be an aqueous ethanol solution, for example, an aqueous 95% ethanol solution.

The amount of the above-mentioned extraction solvent is not particularly limited, and can be used in a ratio of about 1 to 10 liter volume, preferably about 1 to 5 liter volume, per 1 kg of the enzyme-treated clove. In addition, the above-mentioned extraction process can be performed by an extraction method such as extraction at room temperature, hot water extraction, ultrasonic extraction, and reflux cooling extraction for about 30 minutes to 48 hours, preferably about 30 minutes to 24 hours. In one embodiment, the extraction may be carried out by a reflux cooling extraction method at about 80 < 0 > C. Further, the extraction process can be performed in a single or a plurality of circuits, and preferably, about three times. The extract may be obtained in a liquid, semi-solid or powder form, if necessary, by a conventional method, for example, at a temperature of about 30 to 70 캜, by concentration under reduced pressure or drying under reduced pressure.

The present invention provides a composition of foods, medicines and cosmetics having an effect of improving skin wrinkles containing an enzyme-treated clove extract as an active ingredient. Therefore, DPPH radical inhibitory activity, promotion of the production of type-1 procollagen, and reduction of production of MMP-1 and MMP-3 are required to suppress the aging of skin and improve wrinkles.

The enzyme-treated clove extract has excellent antioxidative effect and inhibitory activity of MMP-1, and is excellent in cell protection effect and wrinkle suppressing effect, and thus can be effectively used as a cosmetic composition for improving skin wrinkles. The composition of the food, medicines and cosmetics containing the enzyme-treated clove extract according to the present invention can be formulated into a skin aging-inhibiting agent, a skin wrinkle-improving food, a medicine, and a cosmetic.

The above-mentioned cosmetic composition may be in the form of, for example, a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic (liposome) In the form of a dispersing agent, in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a conical stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant. The above cosmetic composition may further contain, in addition to the enzyme-treated clove extract of the present invention, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, A surfactant, a water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, And may contain adjuvants conventionally used in the cosmetics field, such as any other ingredient commonly used.

In the cosmetic composition containing the enzyme-treated clove extract of the present invention, the extract of the present invention may be added to the cosmetic composition usually contained in an amount of 1 to 15% by weight, preferably 2 to 10% by weight.

When the enzyme-treated clove extract according to the present invention is used as an external preparation for skin, it may further contain at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, , Surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, lipophilic or lipophilic active agents, And any other ingredients conventionally used in external preparations. In addition, the above ingredients can be introduced in amounts commonly used in the dermatological field.

The composition of the present invention may be in the form of a pharmaceutical composition comprising the enzyme-treated clove extract described above and a pharmaceutically acceptable carrier. The pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations and sterilized injection solutions according to a conventional method. The pharmaceutically acceptable carrier may be selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. It also includes diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like. Solid form preparations for oral use include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose ), Gelatin and the like, and may include a lubricant such as magnesium stearate, talc, and the like. Oral liquid preparations include suspensions, solutions, emulsions, syrups, and the like, and may contain diluents such as water and liquid paraffin, wetting agents, sweetening agents, fragrances, preservatives and the like. Examples of the non-aqueous solution include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions and freeze-dried preparations. Non-aqueous solvents and suspensions include vegetable oils such as propylene glycol, polyethylene glycol and olive oil, And the like, and the like.

The dose of the enzyme-treated clove extract contained in the pharmaceutical composition varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but may be suitably selected depending on the case. For example, the above-mentioned clove extract of the enzyme treatment may be administered at a dose of 0.0001 to 100 mg / kg per day, preferably 0.01 to 100 mg / kg per day, It is possible. In addition, the pharmaceutical composition may contain 0.001 to 50% by weight of a clove extract of the enzyme treatment with respect to the total weight of the composition. Such pharmaceutical compositions may be administered to mammals, such as humans, by a variety of routes, for example, by oral, intravenous, intramuscular, or subcutaneous injection.

The present invention also provides a health food for improving skin wrinkles containing an extract of cloves of an enzyme treatment as an active ingredient.

The Clove extract of the enzyme treatment according to the present invention has excellent antioxidative effect and MMP-1 inhibitory activity, and is excellent in cell protection effect and wrinkle suppressing effect, and thus can be effectively used as a health food for improving skin wrinkles.

The health food of the present invention can be used as it is or can be used in combination with other food or food ingredients, and can be suitably used according to conventional methods. There is no particular limitation on the kind of the food. Examples of foods to which the above-mentioned clove extract of the enzyme treatment can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, , Tea, a drink, an alcoholic beverage, and a vitamin complex, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the enzyme-treated clove extract of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the enzyme-treated clove extract of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention can be explained and understood in more detail through a test example. However, these Test Examples and Preparation Examples are for illustrating the present invention, and the scope of the present invention is not limited thereto.

<Enzyme-treated Clove  Preparation and Analysis of Extracts>

1. Preparation of Enzyme-Treated Clove Extract

The clove was pulverized into 20-40 mesh and placed in a flask or glass container. The enzymes obtained in a separate process were dissolved in 10 times the volume of the clove by weight, corresponding to 10-20% of the weight of the clove, and placed in a flask containing the clove. The mixture in the vessel was allowed to react at 50-60 DEG C for 24 hours. After the reaction, the supernatant was separated from the precipitate by centrifugation, and 50% EtOH was added to the precipitate at a weight ratio of 10 times, followed by reflux extraction at 70 ° C for 4 hours. After extraction, the mixture was filtered and concentrated to remove EtOH, and then mixed with the supernatant obtained after the initial reaction, followed by lyophilization.

2. Analysis of Enzyme-Treated Clove Extracts

 (1) Analysis of component change by HPLC

The mobile phase was prepared by mixing water (H2O, 100%) and acetonitrile (CH3CN, 100%) using a PDA HPLC system and Eclipse XDB-C18 column (4.6 x 250 mm, Respectively. When the gradient elution ratio (water: acetonitrile) was 75:25, 68:32, 45:55, 40:60, 0: 100, 0: 100 and 75:25, 10-15, 15-20, 20-25, 25-27, 27-30 and 30-40. The flow rate of the mobile phase was allowed to flow at 1.2 ml / min, and components were analyzed at 203 nm using a UV detector (Fig. 1).

Example 1: Preparation of extract

To 500 g of the enzyme-treated clove, 10 L of a 50 wt% aqueous ethanol solution was added and the mixture was reflux-extracted at 80 캜 for 30 minutes. The extract was filtered, and the obtained filtrate was concentrated in vacuo at 45 DEG C or lower to obtain about 60 g of a semi-solid extract.

Test Example 1: Antioxidant effect

Oxidative stress activates cellular signaling pathways when skin is exposed to ultraviolet light, increases the production of reactive oxygen species such as hydrogen peroxide, and decreases the expression of antioxidant enzymes. This increase in reactive oxygen species changes the structure of genes and proteins, destroys the intracellular homeostasis, causing skin damage and promoting skin aging. The inhibitory activity of DPPH radical, one of the active oxygen species promoting skin aging, is an important index for evaluating antioxidant efficacy.

(Sang S et al., J. Agric. Food Chem. 50 (8), p2459-2463, 2002) using the reducing power of DPPH (1,1-diphenyl-2-picrylhydrazyl, Sigma, USA) The antioxidant activity of the yeast extract according to the present invention was measured according to the method.

An enzyme-treated clove and Arbutin (0.1, 1, 10, 100, 250 μg / ml) dissolved in methanol (180 μl) of 0.2 mM DPPH solution and 20 μl of distilled water were added to a 96-well microplate and cultured at 37 ° C. for 30 minutes After that, the amount of reduced DPPH was measured at 520 nm using a spectrophotometer (Precision Microplate Reader, Molecular Devices, VersaMax), and the activity was compared with a no-added control sample. The test was repeated three times and the results are shown in FIG.

Test Example 2: Measurement of cell viability

The effect of the enzyme-treated clove extract on cell growth of human fibroblasts was evaluated using human dermal fibroblast (HDF) (MCTT Co., Seoul, Korea). HDF was seeded in a DMEM medium (Gibco-BRL, Gaithersburg, MD, USA) containing 10% FBS (fetal bovine serum, Cambrex) in a 40 mm dish at 1.2 × 10 5 / dish and cultured for 1 day. Mu] l of PBS was added thereto, followed by UV irradiation, followed by incubation for 72 hours with an enzyme-treated clone diluted with serum-free DMEM medium.

Thereafter, 1 ml of the culture medium was taken separately and centrifuged and stored. 100 μl of 1 mg / ml of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide) reagent was added to the above- And cultured for 4 hours at 37 占 폚 and 5% CO ₂ wetting conditions. In culture, purple crystals form in living cells. After the incubation for 2 hours, the medium was removed, 800 쨉 L of DMSO was added, the crystal was dissolved in a shaking incubator for 10 minutes, and the absorbance was measured at 570 nm to measure the degree of cell growth. The test was repeated three times, and the results obtained are shown in FIG. From the results in Fig. 3, it can be seen that the enzyme-treated clove has no cytotoxicity. Statistical analysis of the results was performed using the GraphPad Prism program and the significance of the mean value was examined using a one-way analysis of vatiance (ANOVA) with a limit of less than 5%.

Test Example 3: Inhibitory effect of MMP-1, MMP-3 and IL-6

Human fibroblasts were inoculated with cells at a concentration of about 1.2x10 &lt; 5 &gt; in a culture medium of 40 mm cell culture dish, and cultured in a 5% CO ₂ environment at 37 ° C for 24 hours. Thereafter, the ultraviolet ray B was irradiated at 144 mJ / cm 2, and then the enzyme-treated clove extract was replaced with a medium containing 1, 10, and 100 μg / ml and cultured for 3 days. The cultures were then harvested and centrifuged at 7500 rpm for 5 minutes at 4 ° C and analyzed by ELISA using MMP-1, MMP-3 and IL-6 (Human Total MMP-1 kit; MMP-3 kit, Human Total IL-6 kit, R & D Systems, Inc., Minneapolis, MN, USA). The results are shown in Figs. 4, 5 and 6. From the results of FIGS. 4, 5 and 6, it was confirmed that MMP-1, MMP-3 and IL-6 production stimulated by ultraviolet irradiation were inhibited by the enzyme-treated clove extract. From the results of the following, it was confirmed that the effect of suppressing photoaging of nettle was observed.

Manufacturing example  1: Enzyme treated Clove  Containing an extract as an active ingredient Cosmetic  Produce

<1-1> Production of softening longevity

The softening longevity containing the enzyme-treated clove extract of Example 1 as an active ingredient was prepared as shown in Table 1 below.

[Table 1]

<1-2> Preparation of nutritional cream

The nutrient cream containing the enzyme-treated clove extract of Example 1 as an active ingredient was prepared according to the composition shown in Table 2 below.

[Table 2]

Manufacturing example  2: Enzyme-treated Clove  Preparation of medicines containing extracts as active ingredients

&Lt; 2-1 > Preparation of syrup preparation

Syrup preparations containing the enzyme-treated clove extract of Example 1 as an active ingredient were prepared according to the composition shown in Table 3 below.

[Table 3]

Preparation Example 2: Preparation of medicines containing clove extract of enzyme treatment as an active ingredient

&Lt; 2-1 > Preparation of syrup preparation

Syrup preparations containing the enzyme-treated clove extract of Example 1 as an active ingredient were prepared according to the composition shown in Table 3 below.

[Table 4]

250 parts by weight of the enzyme-treated clove extract according to <Example 1>, 175.9 parts by weight of lactose, 180 parts by weight of potato starch and 32 parts by weight of colloidal silicic acid. 10% gelatin solution was added to the mixture, followed by pulverization and passed through a 14-mesh sieve. This was dried, and a mixture obtained by adding 160 parts by weight of potato powder, 50 parts by weight of talc and 5 parts by weight of magnesium stearate was made into tablets.

Manufacturing example  3: Enzyme-treated Clove  Preparation of health food containing extract as active ingredient

Foods containing the enzyme-treated clove extract of Example 1 as an active ingredient were prepared as follows.

<3-1> Production of flour food

0.5-5.0 parts by weight of the enzyme-treated clove extract of Example 1 was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.

<3-2> Manufacture of soups and gravies

0.1 to 5.0 parts by weight of the enzyme-treated clove extract of Example 1 was added to the soup and the juice to prepare health promotion meat product, noodle soup and juice.

<3-3> Preparation of ground beef

10 parts by weight of the enzyme-treated clove extract of Example 1 was added to ground beef to prepare ground beef for health promotion.

<3-4> Manufacture of dairy products

5 to 10 parts by weight of the enzyme-treated clove extract of Example 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

&Lt; 3-5 >

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and then the powder was prepared into a powder having a particle size of 60 mesh by a pulverizer.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then powdered with a particle size of 60 mesh using a pulverizer.

The enzyme-treated clove extract of Example 1 was concentrated under reduced pressure in a vacuum concentrator, dried with a spray and a hot-air drier, and pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.

The grains, seeds, and extracts of Example <1-3> prepared above were blended in the following proportions.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

3 parts by weight of the enzyme-treated clove extract of Example 1,

(0.5 part by weight),

(0.5 parts by weight)

Manufacturing example  4: Enzyme treated Clove  Preparation of beverage containing extract as active ingredient

<4-1> Production of health drinks

(5%), an oligosaccharide (2%), a sugar (2%), a salt (0.5%) and water (75%) and an enzyme-treated clove extract of Example 1 Were uniformly blended and instant sterilized and packaged in small containers such as glass bottles and PET bottles.

<4-2> Production of vegetable juice

5 g of the enzyme-treated clove extract of Example 1 was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice.

<4-3> Preparation of fruit juice

1 g of the enzyme-treated clove extract of Example 1 was added to 1,000 ml of apple or grape juice to prepare fruit juice.

In view of the action and effect of the present invention, which has been shown in accordance with this embodiment, DPPH inhibitory activity, promotion of type-1 procollagen production in human dermal fibroblast (HDF), production of MMP-1 and MMP-3 The effect of inhibiting skin aging and wrinkle improvement effect through inhibiting effect and showing no change in cell survival rate and securing excellent safety can be obtained, The extract can be effectively used as a composition added to cosmetics, foods, medicines and the like.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention. It is therefore intended that such variations and modifications fall within the scope of the appended claims.

Claims (6)

Treated with an enzyme-treated clove extract produced by mixing at least one enzyme selected from alpha-galactosidase or cellulase and clove pulverized with 20-40 mesh and water at 50 to 60 ° C for 24 hours as an active ingredient Including,
Wherein the enzyme, the clove, and the water are mixed in a wince range of 0.1 to 0.2: 1: 10. delete A cosmetic composition comprising the wrinkle-improving composition of claim 1 as an active ingredient. delete A health food composition comprising the wrinkle-improving composition of claim 1 as an active ingredient. delete

Images